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Abstract
Background: Rye contains more fibre and bioactive compounds than other cereals used for bread production.
The fibre and compounds of the fibre complex could provide protection against breast cancer (BC).
Objective: To review the evidence and theoretical background for a role of rye and some of its components in
the prevention of BC.
Design: A short review based to a great extent on the work by scientists in the Nordic countries.
Results: Some of the possible mechanisms by which the fibre complex could reduce BC risk are presented.
The fibre through its effect on fermentation increases esterification of bile acids reducing toxicity of the
free bile acids and is involved in the production of butyrate with potential anticancer effects including BC.
The fibre reduces the enterohepatic circulation of the oestrogens leading to lower plasma oestrogen
concentrations. The fibre complex contains bioactive compounds such as lignans and alkylresorcinols that are
antioxidative and potentially anticarcinogenic. In addition, vitamins, minerals, and phytic acid in rye may
provide protection against BC.
Conclusion: Rye products made from wholegrain rye flour are likely to contribute to reduced BC risk.
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M
any risk factors for breast cancer (BC) have
been identified, one of the more important
being diet. However, it has been difficult to
identify dietary components involved and mechanisms of
action. The results are still controversial. In this short
review the possible BC preventive role of wholegrain rye
products, commonly consumed in all Nordic countries
and the Baltic countries, Poland and Russia, will be
discussed.
Wholegrain and breast cancer (BC)
In 1984 we proposed that a fibre-rich food containing
lignan precursors like wholegrain rye and wheat bread
could protect against both breast and colon cancer (1).
Epidemiological studies have supported that wholegrain
intake may protect against breast and colorectal cancer as
well as diabetes, obesity, and cardiovascular disease
(CVD) (2).
Searching literature for ‘wholegrain and breast cancer’
from Pub Med revealed 39 references, but few of them
relate to wholegrain rye intake. However, in some pig
experiments rye products were separately fed to pigs and
the differences of metabolic effects between wheat and rye
could be studied (3, 4).
Two studies throw some light on the problem of
comparing intake of wholegrain products by dietary
records and assay of plasma enterolactone (ENL),
a metabolite of lignans. It was found in a very large
prospective study comprising 978 cases of BC that there is
no association betweenwholegrain intake and BC risk (5).
In this study food frequency formswere used. However, in
an earlier study by the same group, measuring ENL in
plasma, a clear tendency towards a lower risk for BC with
higher ENL concentration was found, particularly for BC
with the genotype Era (6). Because 4050% of ENL is
formed from lignans in wholegrain products (7), these two
results are contradictory. In the study by Chatenoud et al.
(8), wholegrain intake was associated with lower cancer
risk for all cancers except thyroid cancer.
Mediterranean diet including wholegrain products also
seems protective (9). However, in a large study in USA,
both refined and unrefined grain intake were unrelated to
BC risk (10). Two reviews by Slavin (11, 12) try to explain
the mechanisms of the wholegrain effect but nothing
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short review with emphasis on rye and BC, some
possible mechanisms of protective wholegrain effects
will be discussed.
Oestrogens important risk factors for breast cancer
(BC) and role of fibre intake in oestrogen
metabolism
Oestradiol, the main female sex hormone is produced
almost exclusively in the ovaries in premenopausal
women, but in postmenopausal women the oestrogens
derive from conversion of male sex hormones (androgens)
by aromatisation in various tissues like fat and muscle
tissue. Abundance offat tissue as in obese subjects leadsto
increased production of oestrogens, mainly oestrone, the
oxidation product and primary metabolite of oestradiol.
Oestrone can be converted back to oestradiol but the
main metabolic pathways lead to 2-hydroxylated cathecol
oestrogens and 16a-hydroxyoestrone and oestriol. The
2- and 4-hydroxylated catechol oestrogens and 16a-
hydroxyoestrone have been regarded as carcinogens, but
the opinions are very controversial. Oestrogens stimulate
BC cell growth of oestrogen receptor positive BCs and are
regarded as a risk factor for this disease (13). Fibre can
reduce oestrogen activity by binding and/or fermentation
(see below).
Because oestrogens participate in the so-called enter-
ohepatic circulation (14), diet, particularly fat and fibre,
influence significantly oestrogen disposition and level in
thebody.Themechanismisasfollows:thelivertakesupthe
oestrogensproducedinthebodyand50%isexcretedinthe
bile in the conjugated form coupled mainly to glucuronic
acid and to a small extent to sulphate (15). The glucuronic
acid and the sulphate groups are removed by hydrolysis in
the colon. The free oestrogens are then absorbed but
immediately re-conjugated with glucuronic acid in the
mucosal cells lining the colon and transported to the liver
in theportal vein.A small part enters the portalveinin the
freeform.Someoestrogensarepassingthroughtheliverto
the blood (hepatic vein) and some again into the bile. The
whole circulation takes about 6 h (14).
Because of increasing faecal volumes, a fibre-rich diet
dilutesthecontentoftheintestinereducingconcentrations
of enzymes responsible for the hydrolysis of the oestrogen
conjugates. Since the oestrogens cannot be reabsorbed
fromtheintestineintheconjugatedform,thefibrereduces
oestrogen plasma levels. Fat intake increases absorption of
oestrogens in the colon and a high fat/low fibre diet leads
to high oestrogen levels in the urine and blood, and low
concentration in the stools (1618). Women consuming a
low fibre diet usually also consume a high fat diet
increasing in this way the oestrogen levels and BC risk.
Rye bread and other rye foods, compared to other
cereal products, are particularly rich in fibre and certain
phytochemicals like lignans (19) and alkylresorcinols
(ARs) (20). Rye contains about 1517% fibre of its dry
matter, of which 34% or 20% of total fibre is soluble
fibre and the main part is insoluble fibre. Cellulose and
lignin are important components of the insoluble fibre.
The soluble fibre is mainly arabinoxylans and b-glucans.
By consuming at least 150200 g/day of wholegrain rye
bread and other rye products (see also http://rye.vtt.fi/)
we obtain a considerable part of the daily recommended
intake of vitamins such as vitamin E, thiamin, riboflavin,
niacin, and folate as well as the minerals like zinc, iron,
manganese and magnesium, and some selenium. The
aleurone layer of the kernel contains the main part of
these compounds.
Health effect of rye intake may be related to its fibre
content but also to various bioactive compounds in the
‘fibre complex’, such as lignans, ARs, phytic acid, and
other phenolic compounds. From the point of view of BC
preventionlignanshavegotmuchattentioninrecentyears.
Lignans
The mammalian lignans (nowadays called enterolignans),
ENL and enterodiol (END), are intestinal bacterial
metabolites of plant lignans. Rye has the highest con-
centration of lignans compared to other cereals used for
breaddoughproduction.Theenterolignansareincludedin
the group of phyto-oestrogens because they are weakly
oestrogenic (21) as demonstrated in vivo in the mouse, and
also seem to stimulate production of sexhormone-binding
globulin (SHBG) (22). An increase in SHBG results in
more oestradiol being bound to this protein reducing
the biological activity of oestradiol. Furthermore, the
conversion of androgens to oestrogens in fat and
muscle tissue (called aromatisation) is inhibited by phyto-
oestrogens (23), including lignans.
The lignans were first detected in the urine of human
subjects and monkeys (2426). ENL occurs in nanomolar
to micromolar concentrations in body fluids and in lower
amounts in tissues. Unchanged plant lignans have also
been found and measured in urine (27). The lignans
have numerous biological effects and plants containing
lignans have been used extensively in popular medicine.
The precursors in plants are considered antirheumatic,
anti-inflammatory, antiallergic, antihypertensive, and
syringaresinol (SYR), particularly abundant in rye, en-
hances endurance in rats (28, 29).
High concentrations of lignans occur particularly in
flax and sesame seed, and wholegrain cereals (Table 1 in
Ref. (30)) but also in some vegetables and berries (19, 31).
Vegetarians have the highest urinary excretion and plasma
values of lignans (32). Two plant lignans and precursors
of ENL, matairesinol (MAT), and secoisolariciresinol
(SECO), have been known for more than 25 years (33, 34)
and their occurrence in food has been studied (31, 35, 36).
It has been well known for a long time that there must
be other quantitatively more important precursors of
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relatively recently this area of research has provided
important new results (19, 30, 36, 37) showing that there
exists many other precursors for the enterolignans. These
precursors are pinoresinol (PIN), lariciresinol (LAR),
medioresinol (MED), SYR, and 7-hydroxymatairesinol
(HMR) in addition to SECO and MAT. When these
compounds were incubated with human faecal flora ENL
was produced (37). Also sesamin and lignin can serve as a
precursor for ENL (38, 39).
Originally we suggested that ENL, the main entero-
lignan, is a good biomarker of wholegrain intake,
particularly rye consumption. This was due to the large
consumption of rye bread in Finland. However, later
studies in other than Finnish populations with higher
vegetable and fruit intake and low intake of wholegrain
products showed that ENL did not correlate with
wholegrain intake and sometimes not even with total
fibre intake. This is due to the fact that, in addition to
fruits and vegetables, also wine, tea, coffee, and fruit juice
contain plant lignans (40). Furthermore, it was found
that smoking and obesity (41) decrease plasma ENL and
that antibiotics destroy the bacteria responsible for
the formation of ENL in the colon (42). The effects of
antibiotics on the colonic microflora may last up to 12
14 months and considerably reduces the formation of
ENL and other metabolites. In Finland three studies
dealing with BC and coronary heart disease (CHD)
(4345) show that when rye intake is significant
and correlates with plasma ENL levels, the plasma
ENL concentration is negatively associated with this
disease.
Role of intestinal microflora and fermentation
Faecal bacteria have been identified converting plant
lignan precursors to END and ENL (46, 47). This occurs
in the upper part of the large intestine.
The effect of cereal fibre and fat on oestrogen meta-
bolism (48, 49) is mediated by the intestinal microflora,
particularly in the colon. In both rats and human subjects
anincreaseindietaryfatdecreases theurinaryexcretionof
lignansdespiteidenticalgrainfibreintake(40,50).Obesity
is negatively associated with plasma ENL in women (41).
Thus, if high ENL lowers BC risk, the effect of fat intake
may be an indirect one via reduction of the production of
enterolignans. The intake of wholegrain rye stimulates the
formation of butyrate, a short-chain fatty acid, in the gut.
Simultaneously ENL production increases, but these are
independent phenomena (51). Butyric acid has anticancer
activity and may contribute to an anticancer effect of the
cereal(rye)fibrecomplex.Wemayconcludethatfatintake
reduces ENL formation and fibre intake increases it,
provided that the intestinal microflora is normal and not
changed by intake of antibiotics.
Breast cancer (BC) studies in rodents fed flaxseed and pure
lignans
Flaxseed contains very high amounts of secoisolari-
ciresinol diglucoside (SDG), which is converted in the
gut to END and ENL. Flaxseed and particularly the
purified SDG seem to inhibit the growth of mammary
tumours in experimental rat studies both in the initiation
and promotional phase of the disease. Both tumour
size and multiplicity were influenced. Also the oil
component of flaxseed containing unsaturated fatty acids
contributed to the effect. The results have been reviewed
and discussed by Thompson (52, 53).
Some results in rodents suggest that flaxseed or purified
lignansmayhavethesameeffectonthemammaryglandas
isoflavones from soy when administered prepubertally by
enhancing differentiation of highly proliferative terminal
end bud structures (53). As for isoflavones, intake of
lignans before puberty may be beneficial, because the
increase of differentiation observedin rats seems to reduce
BC risk (5457).
This is in agreement with the results of a recent
Canadian human study in adolescent girls (58). More
than 3,000 cases and the same number of controls were
studied. High lignan or isoflavones, or total phyto-
oestrogenintakeduringadolescencewashighlyprotective,
particularly for the lignans (trend significant, pB0.0001).
The odds ratio (OR) for the highest quartile of intake
compared to the lowest was 0.74 for lignans and 0.81 for
isoflavones. For total phyto-oestrogens it was 0.71 (trend
significant, pB0.0001).
Pure HMR isolated from Norway spruce and fed to
rats is converted to ENL in the large bowel and inhibits,
in physiological concentrations, mammary carcinogenesis
induced with a carcinogen (59). Other important work
with flaxseed and BC is cited in Ref. (30).
Human studies on lignans and breast cancer (BC)
In the beginning of the 1980s we got an opportunity to
measure urinary ENL in 72-h urine samples during four
seasons in small groups of postmenopausal omnivorous
(consume all foods) and vegetarian Boston women as well
as in healthy BC patients after surgical removal of small
breast tumours (60). The diet of the subjects was carefully
recorded using balances. The urinary ENL values in the
BC patients were significantly lower than those of the
control omnivores but particularly lower than those of
the vegetarians. Later three additional groups of young
Finnish women were included into the study including
omnivores, vegetarians, and BC patients (61). In these
Finnish women there was a highly significant correlation
between urinary ENL and grain fibre as well as grain
calorie intake, but we did not separate fibre from wheat
and rye. The mean intake of cereal fibre was only 3.5 g/
day in the postmenopausal BC subjects living in Boston
(60) more than 40 years ago. The low urinary excretion of
Rye and breast cancer
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a country also consuming wholegrain products. These
observations paved the way for research on lignans and
cancer. It was suggested that both fibre and lignans may
be involved in reducing breast and colon cancer risk, and
presented as an extension of the Burkitts original fibre
hypothesis (1, 63).
Many prospective and case-control epidemiological
studies on ENL and BC have been identified and
reviewed (30). No prospective studies show overall
association between lignan intake and plasma ENL
with risk, but in some investigations certain groups of
women seemed to benefit from high levels of ENL (see
below). Most of the case-control studies show a negative
association between plasma concentration of ENL and
BC risk, but all results are not significant. The reasons for
the variable results are many. The establishment of a
persons ENL level needs three different blood samples or
24-h urine collections (30), but in most cases only one
single value has been obtained. In addition to the
numerous factors affecting ENL production in the
gut or its plasma concentration (antibiotics, smoking,
obesity, fat intake, constipation) the dietary source of the
enterolignan precursors in plants may play an important
role as it is likely that fibre, other phytochemicals,
vitamins, and minerals in the food are also playing a
role in cancer prevention. In several studies the lignan
intake is calculated from databases with values only for
SECO and MAT. Even if we would know the content of
plant lignans in all foods we do not know exactly how
effective formation of enterolignans is from certain foods
and from which food source they derive in a particular
subject. If the food source of lignans does not contain any
or very little fibre like wine, orange juice, coffee, and tea
the protective effect may be smaller. According to our
original hypothesis (1, 48) when consuming a non-
supplemented diet, it is the fibre or perhaps mainly
the cereal fibre (now cereal fibre complex), including
the associated lignans and other compounds which are
cancer and CHD protective in human subjects. The
positive results obtained in Eastern Finland in a
region with high cereal (rye) fibre intake regarding
CHD (44), and BC risk (43) support the view that
lignans from rye combined with a fibre effect may be
protective.
The controversial results obtained in prospective and
case control studies have been discussed previously (30).
The observation that women with urinary and other
infections treated with antibiotics may have higher risk
for BC is an indication of a possibly important role of the
intestinal microflora in this disease (64). That intake of
antibiotics may increase BC risk was confirmed in one
(65), but not in two other epidemiological studies (66,
67). We suggested that the increase of risk could be in
part due to reduced ENL levels in the body. However, the
two cohort studies by Horn-Ross (68, 69) finding no
association with lignan intake represent the largest
studies with highest number of cases, but they were
carried out at a time when all the new lignans in foods
were not known and consequently only 10% or less of the
lignans consumed were quantified by calculation of
lignan content of the food.
InamuchsmallerFinnishcase-controlstudycomprising
194BCcasesand208community-basedcontrolsthemean
serum ENL concentration was 20 nmol/l for the healthy
BC subjects and 26 nmol/l for the controls. The OR in the
highest quintile of ENL values compared to the lowest
quintile adjusted for all the known risk factors for BC was
0.38 (43, 70). Low risk was associated with high intake of
rye products, fibre, tea, and vitamin E. Rye contains high
amounts offibre and lignan precursors and alsovitamin E
(http://www.rye.vtt.fi). Tea is also rich in lignans (71).
Judged from these studies a plasma level of about 2060
nmol/l of ENL may reduce risk of BC (70, 72). The
minimumENLlevelindicatingarelativelyhealthylifestyle
has been estimated to 1520 nmol/l, but the optimum level
is likely to be higher than 30 nmol/l. In one prospective
study on BC (73) both the median values for cases and
controls were below 15 nmol/l. This study belongs to the
few in which subjects were excluded if they had taken
antibioticswithin4weeksbeforethesampling,butthisisa
tooshorttimetowaitandthelowvaluessuggest that most
subjects were at risk.
In many studies food records were used and from
them the intake of SECO and MAT was calculated
based on published values or the production of ENL and
END (74) from various plant lignans. In only one study
four lignans were investigated because at that time food
lignan values for PIN and LAR were also available
(75, 76).
The most recent epidemiological publications are
summarised in Table 1 (7781). In the studies using
FFQ four lignan precursors were calculated. Of the three
prospective studies one was negative. In one case-control
study (77) only one group of young premenopausal obese
women, after stratification by BMI, showed an increased
risk when lignan intake was low, and in a Mexican study
(79) consumption of the two plant precursors LAR and
PIN was negatively associated with BC risk.
Effect of lignans on breast cancer (BC) risk
combined with polymorphisms of metabolic enzyme
genes or with BC receptors on human BC risk
In two case-control studies the women who had a
genotype with one A2 allele of CYP 17, that may result
in higher androgen and oestrogen levels, high lignan
levels were associated with a highly significant risk
reduction for BC (82). This is in accordance with the
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woman on HRT (83). A German group found that in
premenopausal women high intake of MATand also high
calculated production of ENL and END were associated
with less risk of BC (84). MAT is with few exceptions
found in significant amounts only in rye and oat
products. Later, this observation was confirmed by the
same group measuring plasma ENL (85). An American
study (86) found that high lignan intake was associated
with lower risk of BC and concluded that ‘dietary lignans
may be important in the etiology of BC, particularly
among premenopausal women’.
Studies in both Denmark and USA found a lower risk
with higher levels of ENL mainly for ERa-negative BC
(6, 87). This could be an explanation for the controversial
results obtained in BC studies. Oestrogen receptor
negative BC is likely to be stimulated by growth factors
and there are indications that in such situations ENL may
be protective (8890). In a Swedish study (78) the reduced
risk was seen only for ERa() and ERb() tumours
with significantly different risk for ERb() and ERb()
tumors. It therefore, seems that certain groups of women
are particularly receptive to the protective effect of ENL.
The protective association was most evident in tumours
that expressed ERa, but not ERb.
The perfect epidemiological study has still to be carried
out separating rye and wheat foods. High levels of ENL
cannot be achieved without consuming wholegrain bread,
particularly rye bread, or by adding linseed or sesame
seeds to the diet. A better biomarker than ENL for cereal
fibre intake such as AR metabolites (91) should be used.
An adequate intake of fibre also seems necessary, in
addition to the lignans, because of its effect on oestrogen
metabolism. Negative association between plasma ENL
or lignan intake and risk seem to be found mainly in
regions with moderate to high intake of wholegrain
cereals in Finland (43), Sweden (92), Denmark (6),
Germany (84, 85), and Australia (93) with relatively
high consumption of rye, but the results are negative or
controversial in countries where wine, juice, tea, and
coffee are the main source of lignans (9497).
Alkylresorcinols (ARs)
Of the common cereals rye has also the highest amounts
of antioxidative and potentially anticarcinogenic ARs
(20, 98), but nothing is known about their relation to BC.
Table 1. Studies during 20082010 on association between plasma levels of enterolactone (ENL) or lignan consumption with breast cancer
Cotterchio et al. (77) Brief food frequency questionnaire (FFQ) n3063
with BC, controls3,430; Canadian women
2574 years old. Lignans calculated from databases
Reduced breast cancer risk among premenopausal
women. Following stratification by BMI, the risk
reduction was confined to obese women
Sonestedt et al. (78) ENL in plasma by TR-FIA
a (prospective) BC cases
(age 4573 years, controls (age 4681). After excluding
some subjects due to insufficient data 366 cases and
733 controls remained
Reduced BC risk for ERa() and ERb() tumours.
Dietary fibre, fruits, and berries and high-fibre bread
showed statistically significant negative association with
plasma ENL. Values of ENL above
16 nmol/l were associated with reduced BC risk.
Reduced risk was only found for ERa() and
ERb() cancer
Torres-Sanchez et al. (79) FFQ 141 cases with BC, 141 hospital controls.
Aged 2179 years, which had been living in
Mexico City at least 20 years. Published values for
phytoestrogens in Mexican food were used
Consumption of lariciresinol and pinoresinol was
negatively associated with BC risk
Sonestedt et al. (80) ENL by TR-FIA (prospective) 365 cases and
728 hospital controls with various diseases
BC risk was not significantly associated with any of the
selected polymorphisms. There was a tendency for an
interaction between a polymorphism of intron 3 of ERa
(rs2347867) and ENL concentration (P0.07). An
inverse association among carriers of the minor allele
(G) (P0.007) was found. Conclusion: The protective
association of ENL is reasonably robust across the
investigated genotypes
Ward et al. (81) (Prospective) 244 BC cases and 941 controls
aged 40 to 79 years (EPICNorfolk).
Seven days dietary records
Method:
aTR-FIAtime-resolved fluoroimmunoassay
No association between lignan intake and breast cancer
risk
Earlier studies have been summarised in Tables 3 and 4 in Ref. (30).
aTR-FIA, time-resolved fluoroimmunoassay.
Rye and breast cancer
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are low in healthy Finnish women with operated BC
indicating low consumption of wholegrain products
including rye bread (99). Studies on ARs and cancer
will continue to obtain larger materials.
Conclusion
The results indicate that the association of wholegrain
products and lignans with BC is very complex. However,
the original hypothesis (1) that fibre, with associated
lignans, may be protective with regard to BC has been at
least partly supported.
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